Megan Baldwin, PhD is CEO and Managing Director of Opthea Limited with over 20 years of experience in research and developing therapies for cancer and ophthalmic indications. Dr Baldwin joined Opthea in 2008, an ASX-listed biotechnology company developing biologics for serious retinal diseases.  Previously Dr Baldwin was employed at Genentech (now Roche), which included several years as a researcher in the angiogenesis group before moving to Genentech’s commercial division in the market planning department. Dr Baldwin holds a PhD in Medicine from the University of Melbourne, having conducted her doctoral studies at the Ludwig Institute for Cancer Research on the biology of VEGF-C/D and is a director of Ausbiotech.